Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cyclin-dependent kinase inhibitors - Virostatics

Next Previous
Drug Profile

Research programme: cyclin-dependent kinase inhibitors - Virostatics

Latest Information Update: 28 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Virostatics
  • Class Antineoplastics; Antiretrovirals; Antivirals; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; Cyclin-dependent kinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical COVID 2019 infections
  • No development reported Cancer; Epstein-Barr virus infections; Hepatitis B; HIV infections; Varicella zoster virus infections
  • Discontinued Ebola virus infections; Herpes simplex virus type 1 infections; Herpes simplex virus type 2 infections; Human papillomavirus infections

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for preclinical development in Cancer in Italy (PO)
  • 28 Dec 2024 No recent reports of development identified for preclinical development in HIV-infections in Italy (PO)
  • 27 Mar 2023 Preclinical trials in COVID-2019 infections in Italy (PO) before March 2023(Virostatics pipeline, March 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top